Doxorubicin Clinical Trials

• ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
  ClinicalTrials.gov Identifier: NCT00003034 - Active, not recruiting
  localized malignant mesothelioma; advanced malignant mesothelioma; recurrent malignant mesothelioma
  
• Osteosarcoma1999-A Study Of Intensive Chemotherapy Utilizing Ifosfamide, Carboplatin, and Doxorubicin for Adjuvant Chemotherapy For Treatment Of Osteosarcoma
  ClinicalTrials.gov Identifier: NCT00145639 - Active, not recruiting
  Osteosarcoma
  
• Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients with Non-Small-Cell Lung Carcinoma (NSCLC)
  ClinicalTrials.gov Identifier: NCT00082472 - Active, not recruiting
  NSCLC
  
• Preoperative Treatment of Breast Cancer with Two Different Sequential Treatment Regimens
  ClinicalTrials.gov Identifier: NCT00149214 - Active, not recruiting
  Breast Neoplasms
  
• Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
  ClinicalTrials.gov Identifier: NCT00036790 - Active, not recruiting
  Cancer
  
• Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
  ClinicalTrials.gov Identifier: NCT00003350 - Active, not recruiting
  epidemic Kaposi's sarcoma
  
• Vincristine, DOXIL® (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00344422 - Active, not recruiting
  M-Protein; Multiple Myeloma; Myeloma; Myeloma Proteins
  
• ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
  ClinicalTrials.gov Identifier: NCT00016172 - Active, not recruiting
  Leukemia; Lymphoma; Eye Cancer
  
• Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00027989 - Active, not recruiting
  stage IV breast cancer
  
• Liposomal Doxorubicin in Treating Patients With Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00004014 - Active, not recruiting
  Quality of Life; recurrent prostate cancer
  
• Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
  ClinicalTrials.gov Identifier: NCT00030784 - Active, not recruiting
  adult soft tissue sarcoma
  
• 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
  ClinicalTrials.gov Identifier: NCT00079014 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women with Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00005980 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00002721 - Active, not recruiting
  recurrent prostate cancer
  
• A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
  ClinicalTrials.gov Identifier: NCT00002318 - Active, not recruiting
  Sarcoma, Kaposi; HIV Infections
  
• Octreotide and Doxorubicin in Treating Patients With Advanced Cancer
  ClinicalTrials.gov Identifier: NCT00008073 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Phase I/II Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients with Advanced Stages Hodgkin''s Lymphoma
  ClinicalTrials.gov Identifier: NCT00147875 - Active, not recruiting
  Hodgkin''s Disease
  
• Doxorubicin in Treating Women With Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00003165 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
  ClinicalTrials.gov Identifier: NCT00003212 - Active, not recruiting
  Soft Tissue Sarcoma; Uterine Cancer
  
• VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin
  ClinicalTrials.gov Identifier: NCT00004030 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel Or Doxorubicin in Locally Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00123929 - Recruiting
  Breast Cancer
  
• Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone OR Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab Followed by Vaccine Therapy Plus Sargramostim in Treating Patients With Stage II, Stage III, or Stage IV Follicular Lymphoma
  ClinicalTrials.gov Identifier: NCT00019981 - Recruiting
  Lymphoma
  
• Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00003682 - Active, not recruiting
  stage IV prostate cancer; recurrent prostate cancer
  
• Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00003035 - Active, not recruiting
  stage IIIB breast cancer; stage IIIA breast cancer
  
• Doxorubicin With or Without Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
  ClinicalTrials.gov Identifier: NCT00079027 - Active, not recruiting
  advanced adult primary liver cancer; adult primary hepatocellular carcinoma
  
• Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00006825 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Bortezomib and Liposomal Doxorubicin in Treating Patients With Multiple Myeloma
  ClinicalTrials.gov Identifier: NCT00088855 - Active, not recruiting
  stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
  
• The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (Study P04445)
  ClinicalTrials.gov Identifier: NCT00266799 - Recruiting
  Breast Cancer
  
• Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
  ClinicalTrials.gov Identifier: NCT00005800 - Active, not recruiting
  stage IIIB breast cancer; stage IIIA breast cancer; inflammatory breast cancer
  
• Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
  ClinicalTrials.gov Identifier: NCT00080782 - Active, not recruiting
  recurrent prostate cancer; stage IV prostate cancer; bone metastases
  
• Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors
  ClinicalTrials.gov Identifier: NCT00305084 - Active, not recruiting
  Cancer
  
• Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
  ClinicalTrials.gov Identifier: NCT00004067 - Active, not recruiting
  stage II breast cancer; stage IIIA breast cancer
  
• Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) With or Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma
  ClinicalTrials.gov Identifier: NCT00038142 - Recruiting
  Ewing's Sarcoma
  
• Doxorubicin Plus External-Beam Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
  ClinicalTrials.gov Identifier: NCT00004109 - Active, not recruiting
  recurrent adult soft tissue sarcoma; stage III adult soft tissue sarcoma
  
• Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer
  ClinicalTrials.gov Identifier: NCT00004175 - Active, not recruiting
  stage IIIB breast cancer; stage IIIA breast cancer
  
• Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma (Kidney Cancer)
  ClinicalTrials.gov Identifier: NCT00068393 - Active, not recruiting
  stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer
  ClinicalTrials.gov Identifier: NCT00032162 - Active, not recruiting
  Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; uterine sarcoma; ovarian sarcoma; ovarian carcinosarcoma
  
• Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin
  ClinicalTrials.gov Identifier: NCT00288431 - Active, not recruiting
  Cancer; Sarcoma
  
• Doxorubicin and Paclitaxel in Treating Women Who are Undergoing Surgery For Breast Cancer
  ClinicalTrials.gov Identifier: NCT00096291 - Active, not recruiting
  stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer
  
• Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00004925 - Active, not recruiting
  stage IIIB breast cancer; inflammatory breast cancer; stage IV breast cancer; recurrent breast cancer
  
• Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
  ClinicalTrials.gov Identifier: NCT00083226 - Active, not recruiting
  adult primary hepatocellular carcinoma; advanced adult primary liver cancer; recurrent adult primary liver cancer; ...
  
• Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
  ClinicalTrials.gov Identifier: NCT00052312 - Active, not recruiting
  recurrent endometrial cancer; stage III endometrial cancer; stage IV endometrial cancer; endometrial papillary carcinoma
  
• Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
  ClinicalTrials.gov Identifier: NCT00081159 - Active, not recruiting
  recurrent prostate cancer; stage IV prostate cancer; bone metastases
  
• Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00079261 - Active, not recruiting
  adult diffuse large cell lymphoma; adult lymphomatoid granulomatosis; anaplastic large cell lymphoma; angioimmunoblastic T-cell lymphoma; ...
  
• Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISION V)
  ClinicalTrials.gov Identifier: NCT00261378 - Active, not recruiting
  Primary Liver Cancer
  
• Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
  ClinicalTrials.gov Identifier: NCT00061984 - Recruiting
  adult soft tissue sarcoma
  
• Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
  ClinicalTrials.gov Identifier: NCT00004248 - Active, not recruiting
  recurrent adult primary liver cancer; adult primary hepatocellular carcinoma; localized unresectable adult primary liver cancer
  
• Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma
  ClinicalTrials.gov Identifier: NCT00004123 - Active, not recruiting
  adult liposarcoma; stage IIC adult soft tissue sarcoma; recurrent adult soft tissue sarcoma; adult leiomyosarcoma; ...
  
• Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00063934 - Active, not recruiting
  stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer; Male Breast Cancer
  
• Radiation Therapy With or Without Doxorubicin and Vinblastine in Treating Patients With Stage I or Stage II Hodgkin's Disease
  ClinicalTrials.gov Identifier: NCT00002495 - Active, not recruiting
  stage II adult Hodgkin's disease; stage I adult Hodgkin's disease
  
• SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
  ClinicalTrials.gov Identifier: NCT00005822 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer; stage IIIB breast cancer; inflammatory breast cancer; Male Breast Cancer
  
• Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
  ClinicalTrials.gov Identifier: NCT00006377 - Active, not recruiting
  stage III endometrial cancer; stage IV endometrial cancer; recurrent endometrial cancer
  
• Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00016406 - Active, not recruiting
  stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; inflammatory breast cancer
  
• Carboplatin With or Without Liposomal Doxorubicin in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00043082 - Active, not recruiting
  peritoneal cavity cancer; recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer
  
• Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00004162 - Active, not recruiting
  AIDS-related diffuse small cleaved cell lymphoma; AIDS-related small noncleaved cell lymphoma; AIDS-related diffuse mixed cell lymphoma; ...
  
• VX-710, Doxorubicin, and Vincristine in Treating Patients With Recurrent Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00003847 - Active, not recruiting
  intermediate type small cell lung cancer; Recurrent Small Cell Lung Cancer
  
• Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
  ClinicalTrials.gov Identifier: NCT00047229 - Active, not recruiting
  adult primary hepatocellular carcinoma; advanced adult primary liver cancer; localized unresectable adult primary liver cancer; ...
  
• Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00074139 - Active, not recruiting
  stage IIIA breast cancer; recurrent breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer
  
• Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer
  ClinicalTrials.gov Identifier: NCT00004236 - Active, not recruiting
  stage III gastric cancer; stage III esophageal cancer; stage IV esophageal cancer; Adenocarcinoma of the Esophagus; recurrent gastric cancer; ...
  
• Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00193037 - Active, not recruiting
  Breast Cancer
  
• Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00538525 - Active, not recruiting
  Breast Cancer
  
• Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer
  ClinicalTrials.gov Identifier: NCT00193115 - Active, not recruiting
  Breast Cancer
  
• Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer
  ClinicalTrials.gov Identifier: NCT00201708 - Active, not recruiting
  Breast Cancer
  
• Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00002576 - Active, not recruiting
  Lymphoma
  
• Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer
  ClinicalTrials.gov Identifier: NCT00093834 - Recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads
  ClinicalTrials.gov Identifier: NCT00054951 - Active, not recruiting
  Hepatocellular Carcinoma
  
• Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors
  ClinicalTrials.gov Identifier: NCT00093444 - Active, not recruiting
  Liver Cancer; Metastatic Cancer
  
• MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00326456 - Active, not recruiting
  Ovarian Cancer
  
• Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
  ClinicalTrials.gov Identifier: NCT00436709 - Active, not recruiting
  Breast Cancer
  
• A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00190489 - Active, not recruiting
  Breast Cancer; Neoplasm Metastasis
  
• Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00080847 - Active, not recruiting
  contiguous stage II adult diffuse large cell lymphoma; noncontiguous stage II adult diffuse large cell lymphoma; ...
  
• Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours
  ClinicalTrials.gov Identifier: NCT00189410 - Active, not recruiting
  Cancer of the Ovary Treated as 2nd Line Therapy; Muellerian Mixed Tumours; Tumours of the Uterus; Cervical Cancers; Non-Epithelial Ovarian Tumours
  
• Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer
  ClinicalTrials.gov Identifier: NCT00544765 - Active, not recruiting
  Breast Cancer
  
• Bortezomib-Dexamethasone-Doxorubicin-Study
  ClinicalTrials.gov Identifier: NCT00401804 - Recruiting
  Multiple Myeloma; Renal Insuficiency
  
• The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity
  ClinicalTrials.gov Identifier: NCT00530101 - Recruiting
  Cardiac Diseases
  
• Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
  ClinicalTrials.gov Identifier: NCT00070447 - Active, not recruiting
  contiguous stage II mantle cell lymphoma; noncontiguous stage II mantle cell lymphoma; stage III mantle cell lymphoma; stage IV mantle cell lymphoma
  
• Total Therapy II
  ClinicalTrials.gov Identifier: NCT00083551 - Active, not recruiting
  Multiple Myeloma
  
• Doxorubicin and Radiofrequency Ablation Therapy for Metastatic Liver Tumors
  ClinicalTrials.gov Identifier: NCT00090805 - Recruiting
  
  
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma
  ClinicalTrials.gov Identifier: NCT00002740 - Active, not recruiting
  disseminated neuroblastoma
  
• Preoperative Thalidomide With Radiation Therapy for Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy, Doxorubicin, Ifosfamide, and Dacarbazine for Patients with High or Intermediate Grade Primary Soft Tissue Sarcom
  ClinicalTrials.gov Identifier: NCT00089544 - Active, not recruiting
  stage I adult soft tissue sarcoma; stage II adult soft tissue sarcoma; stage III adult soft tissue sarcoma; recurrent adult soft tissue sarcoma
  
• Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00004197 - Active, not recruiting
  Lymphoma
  
• Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)
  ClinicalTrials.gov Identifier: NCT00538603 - Active, not recruiting
  Epithelial Ovarian Cancer
  
• Ixabepilone and Liposomal Doxorubicin in Treating Patients With Advanced Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00182767 - Recruiting
  Breast Cancer; Fallopian Tube Cancer; ovarian epithelial cancer; peritoneal cavity cancer
  
• Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00098579 - Recruiting
  gastrointestinal stromal tumor; recurrent adult soft tissue sarcoma; stage IV adult soft tissue sarcoma
  
• Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer
  ClinicalTrials.gov Identifier: NCT00006198 - Active, not recruiting
  Liver Cancer
  
• DTPACE followed by Tandem Transplant with MEL 200 versus MEL/DTPACE Hybrid and DTPACE Consolidation
  ClinicalTrials.gov Identifier: NCT00083915 - Active, not recruiting
  Multiple Myeloma
  
• Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
  ClinicalTrials.gov Identifier: NCT00003296 - Active, not recruiting
  recurrent adult primary liver cancer; localized gallbladder cancer; advanced adult primary liver cancer; cholangiocarcinoma of the gallbladder; ...
  
• Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00365417 - Active, not recruiting
  Breast Cancer
  
• Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00524810 - Active, not recruiting
  Metastatic Breast Cancer
  
• Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma
  ClinicalTrials.gov Identifier: NCT00392340 - Recruiting
  Brain and Central Nervous System Tumors
  
• Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma
  ClinicalTrials.gov Identifier: NCT00025623 - Active, not recruiting
  disseminated neuroblastoma
  
• Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00002715 - Active, not recruiting
  adult Hodgkin's lymphoma
  
• Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00003214 - Active, not recruiting
  Ovarian Cancer
  
• Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer
  ClinicalTrials.gov Identifier: NCT00003050 - Active, not recruiting
  Breast Cancer
  
• Combination Chemotherapy Plus Interferon alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
  ClinicalTrials.gov Identifier: NCT00004039 - Active, not recruiting
  Lymphoma
  
• Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
  ClinicalTrials.gov Identifier: NCT00002601 - Active, not recruiting
  Bone Cancer; Soft Tissue Sarcoma
  
• Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
  ClinicalTrials.gov Identifier: NCT00070564 - Recruiting
  stage I breast cancer; stage II breast cancer; stage IIIA breast cancer; stage IIIC breast cancer; Male Breast Cancer
  
• Reduction of Immunosuppression Plus Interferon alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
  ClinicalTrials.gov Identifier: NCT00002657 - Active, not recruiting
  Lymphoma; Multiple Myeloma
  
• Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00018954 - Active, not recruiting
  Lymphoma; Leukemia
  
• Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
  ClinicalTrials.gov Identifier: NCT00255801 - Recruiting
  Lymphoma